Aptevo Therapeutics (APVO) Enterprise Value (2015 - 2026)
Aptevo Therapeutics (APVO) posted Enterprise Value of -$14.5 million for Q1 2026, up 32.81% sequentially from -$21.6 million in Q4 2025, and down 579.06% YoY from $3.0 million in Q1 2025.
Aptevo Therapeutics (APVO) Enterprise Value (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Enterprise Value for 12 years, with the latest figure at -$14.5 million in Q1 2026.
- Quarterly Enterprise Value fell 579.06% year-over-year to -$14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.5 million (down 579.06% YoY) and the FY2025 annual result came in at -$21.6 million, down 1730.57% from the prior year.
- Enterprise Value grew to -$14.5 million in Q1 2026 per APVO's latest filing, from -$21.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1.1 million in Q4 2022 and troughed at -$36.2 million in Q1 2022.
- A 5-year average of -$13.4 million and a median of -$10.2 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value surged 97.7% in 2022, then slumped 1730.57% in 2025.
- Over 5 years, Enterprise Value stood at -$1.1 million in 2022, then tumbled by 1485.74% to -$16.9 million in 2023, then jumped by 93.01% to -$1.2 million in 2024, then plunged by 1730.57% to -$21.6 million in 2025, then jumped by 32.81% to -$14.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$14.5 million, -$21.6 million, and -$3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 2.12 Bn |
| 10 | Aptevo Therapeutics | 3.40 Mn | -6.40 Mn | - | -9.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.80 Mn |
| Mar 31, 2026 | -14.53 Mn |
| Dec 31, 2025 | -21.62 Mn |
| Sep 30, 2025 | -3.23 Mn |
| Jun 30, 2025 | -8.10 Mn |
| Mar 31, 2025 | -2.14 Mn |
| Dec 31, 2024 | -1.18 Mn |
| Sep 30, 2024 | -7.75 Mn |
| Jun 30, 2024 | -8.07 Mn |
| Mar 31, 2024 | -10.25 Mn |
| Dec 31, 2023 | -16.90 Mn |
| Sep 30, 2023 | -1.61 Mn |
| Jun 30, 2023 | -16.97 Mn |
| Mar 31, 2023 | -25.33 Mn |
| Dec 31, 2022 | -1.07 Mn |
| Sep 30, 2022 | -22.58 Mn |
| Jun 30, 2022 | -29.98 Mn |
| Mar 31, 2022 | -36.25 Mn |
| Dec 31, 2021 | -46.30 Mn |
| Sep 30, 2021 | -54.64 Mn |